Table 3.

Tumor growth inhibition and tumor growth delay of evofosfamide in NPC xenograft models

Group	TGI (%)	TGD500 (day)	TGD1000 (day)
Control	0	10.4	13.2
DDP	42	11.4	18.3
Evofosfamide 50 μmol/L	43	11.2	15.4
Evofosfamide 50 μmol/L + DDP	49	11.3	18.9
Evofosfamide 75 μmol/L	55	11.4	21.2
Evofosfamide 75 μmol/L + DDP	71	11.2	N/A

TGD₅₀₀ and TGD₁₀₀₀ were determined as the average increase in time for the treated tumor to reach a size of 500 or 1000 mm³ compared with the control group

TGI tumor growth inhibition, TGD tumor growth delay